Speakers and Chairs
Dimitri Kullmann is a professor of neurology at the UCL Queen Square Institute of Neurology, London. He trained in medicine and physiological sciences in Oxford and London, and obtained a DPhil at Oxford. After a post-doctoral fellowship at UCSF he completed neurology training in London. His research interests span fundamental mechanisms of synaptic transmission, neurological channelopathies and gene therapy for epilepsy. He is a Fellow of the Academy of Medical Sciences and of the Royal Society, and was the Editor of Brain from 2014 to 2020.
Professor Samuel Berkovic is Laureate Professor in the Department of Medicine, University of Melbourne, and Director of the Epilepsy Research Centre at Austin Health. His medical degree and doctorate were completed at the University of Melbourne before he undertook a 3-year Fellowship at McGill University. He returned to Melbourne in 1987 where he is a practicing neurologist and clinical researcher with a special interest in establishing close research links with basic scientists.
His early work was in neuroimaging where he was a pioneer in the application of MRI and single photon emission computed tomography in epilepsy, and especially epilepsy surgery. This work was rapidly applied to routine clinical use and remains so today. In the late 1980s he realized the potential for clinical genetic research in epilepsy, utilizing the NHMRC twin registry and working with large pedigrees. This led, together with molecular genetic collaborators in Adelaide and Germany, to the discovery of the first gene for epilepsy in 1995. Subsequently he, Ingrid Scheffer and their group have been involved the discovery of many of the known epilepsy genes. This has changed the conceptualisation of the causes of epilepsy, is having a major impact on directions of epilepsy research, and has directly translated to impacting daily clinical diagnosis and counselling, as well as refining treatment. He heads a large Program Grant integrating genetic, imaging and physiological studies in epilepsy. His current passions are completing the understanding of the complex genetic architecture of epilepsies and developing precision therapies for severe genetic epilepsies.
He was elected a Fellow of the Australian Academy of Science in 2005, Fellow of the Royal Society in 2007, Companion of the Order of Australia in 2014 and a member of the National Academy of Medicine in 2017. Together with Ingrid Scheffer, he was awarded the Prime Minister’s Prize for Science in 2014.
Catherine Schevon is Associate Professor of Neurology in the College of Physicians and Surgeons at Columbia University. Prior to her medical training, she studied electrical engineering and computer science, and worked in VLSI design at AT&T Bell Laboratories. She attended medical school at the University of Pennsylvania, and completed an epilepsy fellowship at Columbia in 2004. Dr. Schevon’s research focuses on linking the cellular processes that occur during seizures to their expression in microelectrode and clinical EEG recordings, in order to inform the clinical process of seizure localization.
Matthew Walker is Professor of Neurology at UCL Queen Square Institute of Neurology, and a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. He graduated from Cambridge University in Physiology and then completed his medical training at St Thomas’ Hospital, London, and his PhD at University College London. He has published over 250 peer-reviewed papers on both laboratory and clinic research including studies into the mechanisms regulating brain excitability, epilepsy surgery, status epilepticus and novel treatments of epilepsy. He was an Associate Editor of Brain. He is President of the British Branch of International League against Epilepsy (ILAE), Chair of the trustees of Epilepsy Research UK, Secretary of ILAE-Europe and Chair of the ILAE task force on translational Research. He was made an ILAE ambassador for epilepsy in 2013.
Professor Anne Rosser is a Neuroscientist and Honorary Consultant Neurologist with a special interest in neurodegeneration, in particular Huntington’s Disease with which she has been involved since 1994. She is current Chair of the European Huntington’s Disease Network. She directs the Cardiff University Brain Repair Group, where the key focus is on repair and regeneration in neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, and led the FP7 Consortium Repair-HD which addressed a range of preclinical and clinical questions important in translating stem cell therapies for Huntington’s disease. Along with Professors Gray and Busse, she runs an ongoing clinical trial of fetal cell neural Transplantation in Huntington’s Disease (TRIDENT).
Professor John Hardy Following his PhD, Hardy did postdoctoral research at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, England and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College London in 1985 and initiated genetic studies of Alzheimer’s disease there. He became Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to National Institute on Aging, Bethesda, Maryland, as Chief of the Laboratory of Neurogenetics in 2001. In 2007 he took up the Chair of Molecular Biology of Neurological Disease at the Reta Lila Weston Institute of Neurological Studies, University College London. On 29 November 2015, he was awarded the Breakthrough Prize and in 2018 jointly the Brain Prize from The Lundbeck Foundation in Denmark
Professor Bart De Strooper is the founding director of the UK Dementia Research Institute (UK DRI). He is a researcher in Alzheimer’s disease, and supervises laboratories based in the UK DRI at the Francis Crick Institute in London and in the VIB laboratory at the KU Leuven in Belgium. Bart De Strooper’s research is focussed on translating genetic findings into mechanisms of neurodegenerative diseases and drug targets. He is best known for his work on the presenilins and gamma-secretase, and more recently for his work on the cellular theory of Alzheimer’s Disease. He was elected to the Academy of Medical Sciences Fellowship in 2020, and has received several awards including the Potamkin prize, the Metlife Foundation Award for Medical Research, Alois Alzheimer’s prize, the highly prestigious Brain Prize 2018 and Commander in the Order of Leopold I.
Sarah Tabrizi is Director of the UCL Huntington’s Disease (HD) Centre, Joint Head of Department Neurodegenerative Disease at the UCL Queen Square Institute of Neurology, a Principal Investigator at the UK Dementia Research Institute, and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. In addition to a basic bench science programme focussing on basic cellular mechanisms of neurodegeneration in HD that can be harnessed for therapeutics, she also leads a large translational research programme that is working towards finding effective disease-modifying treatments for HD. She was global clinical PI on the world’s first gene targeting study for HD using anti-sense oligonucleotide therapy. Sarah was elected as a Fellow of the UK Academy of Medical Sciences in 2014. In 2017 she received the seventh Leslie Gehry Brenner Prize for Innovation in Science awarded by the Hereditary Disease Foundation. In 2018 she received the Cotzias Award from the Spanish Society of Neurology, and in 2019 the Yahr Award at the World Congress for Neurology and the Alexander Morison Medal from the Royal College of Physicians of Edinburgh.
Masud Husain is Professor of Neurology & Cognitive Neuroscience at the University of Oxford and Wellcome Trust Principal Research Fellow. He leads the Neurological Conditions theme of the Oxford Biomedical Research Centre and is Professorial Fellow at New College, Oxford. His research focuses on mechanisms underlying memory and motivation deficits in healthy people and patients with neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease and small vessel cerebrovascular disease. Masud is Co-Chair of the European Academy of Neurology Scientific Panel on Higher Cortical Functions and becomes Editor of Brain in January, 2021.
As Professor of Cognitive Neurology, James Rowe studies the mechanisms and potential treatments for Progressive Supranuclear Palsy, Parkinson’s disease and frontotemporal dementia. He trained in medical sciences and experimental psychology at Cambridge, before clinical studies in Oxford and his PhD at the Institute of Neurology, London. After further specialist training in Copenhagen, he returned to Cambridge in 2005. He is Associate Director of DPUK, leading the academic-industrial partnership for experimental medicine. He leads the Centre for Frontotemporal Dementia and the Clinical program within the Centre for Parkinson-plus, together with regional NHS clinics for these disorders, providing seamless integration of clinical care with research innovations. With the support of the Wellcome Trust, MRC and NIHR his team combines advanced methods in positron emission tomography, magnetic resonance imaging, magnetoencephalography, and computational modelling in order to measure the impact of disease and treatment on human brain function. The integration of multimodal brain imaging, genetics, pharmacology and computational modelling provides a powerful platform to understand neurological disease, and to assess the efficacy of novel treatments.
Fiona Kumfor is a National Health and Medical Research Council (NHMRC) Career Development Fellow and Clinical Neuropsychologist at the University of Sydney. She completed her PhD at the University of New South Wales and Masters in Clinical Neuropsychology at Macquarie University. Combining her clinical training in neuropsychology and research expertise in cognitive neuroscience, her work investigates social cognition in clinical syndromes with a focus on dementia, and aims to improve diagnosis and prognosis of dementia, while also informing neurobiological models of complex human behaviours. She is a previous recipient of the Australian Psychological Society Early Career Researcher Award (2018) and the University of Sydney’s Vice Chancellor’s Award for Outstanding Early Career Research (2019). Fiona is currently Member-at-Large for the International Neuropsychological Society and Finance Chair of the International Society for Frontotemporal Dementias.
Olga Ciccarelli is a NIHR Research Professor of Neurology at University College London (UCL). She studied Medicine and the completed her training in Neurology at the University of Rome, Italy. She then came to London with the Jacqueline Du Pre award from the MSIF and a studentship from the University of Rome. After her PhD in Neurological Science at UCL, she was awarded a Wellcome Trust Advanced Clinical Fellowship. In 2019 she became a NIHR Research Professor. She is the Head of Neuroinflammation Research Department at the UCL Queen Square Institute of Neurology, whose main focus is research into multiple sclerosis (MS). She has secured funding from research councils and charities for her work, and has authored more than 160 papers in her research field. She is the Deputy Editor of Neurology, and leads on the Neuroimmunology portfolio. In 2020, she has become a Guarantor of Brain. She is the Topic Advisor for the National Institute for Health and Care Excellence (NICE) guidelines in MS committee. She has a strong commitment to patient care, runs specialist MS outpatient clinics, and aims to bring innovation into the treatment pathways for people with MS in the NHS.
Veronique Miron obtained her PhD in 2009 in Neurological Sciences from McGill University (Canada), funded by studentships from the Natural Sciences and Engineering Research Council and the Canadian Institutes of Health Research, and was awarded the European Charcot Foundation Young Investigator Award. Following a brief postodoc in Neuroimmunology at the Montreal Neurological Institute, she carried out a postdoc in Regenerative Medicine at The Scottish Centre for Regenerative Medicine, funded by the Multiple Sclerosis Society of Canada. She is now a Senior Lecturer in the MRC Centre for Reproductive Health and an MRC/ MS Society Career Development Fellow, leading a team of 5 researchers.
Veronique’s research focuses on investigating the regenerative properties of inflammation to drive central nervous system white matter regeneration, with implications for neurological disorders with high worldwide prevalence (such as cerebral palsy and MS). She has >14 years of research experience in regenerative medicine, myelin biology and neuroimmunology, including proficiency developing and applying in vitro/ ex vivo/ in vivo modelling of neurological disease, transgenic approaches, advanced imaging platforms, high through-put imaging/analysis, and neuropathological analysis. She has authored 31 publications, including in Nature Neuroscience, Acta Neuropathologica, and Annals of Neurology.
She is an active champion of equal opportunity in research, heading the Athena Swan postgraduate working group, writing blogs on women in research, and chairing the Power Hour at the GRC Myelin conference. She is also the founder and organizer for Edinburgh’s first Microglia Club.
Dr. Yeh is a graduate of Harvard University (AB). She received an MA from McGill University in Montreal, Quebec and her MD at McMaster University in Hamilton, Ontario. She completed paediatrics training at McMaster University and paediatric neurology training at SUNY Buffalo, where she developed and co-directed the Pediatric MS and Demyelinating Disorders Center of Excellence. She is currently an Associate Professor of Paediatrics (Neurology) at the University of Toronto in Ontario, Canada, where she is the director of the MS and Demyelinating Disorders Program at The Hospital for Sick Children (SickKids). She is the Education Director in the Division of Neurology at SickKids, and the Director of the paediatric neurology training program at SickKids and the University of Toronto. Her research interests are in visual and neuro-cognitive outcomes in paediatric demyelinating conditions, rehabilitative interventions for this population, as well as therapies for paediatric MS.
Mary M. Reilly graduated from University College Dublin in 1986, received her MD in 1996, FRCP in 2002 and FRCPI in 2003. She was appointed a consultant neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square in 1998 and a Professor of Clinical Neurology at UCL in 2010. She leads the peripheral nerve clinical and research group and is head of the Division of Clinical Neurology in UCL Queen Square Institute of Neurology. She runs a research program in the inherited neuropathies encompassing gene identification, pathogenetic studies, natural history studies, development of outcome measures and conducting clinical trials. She is the immediate Past President of the Association of British Neurologist (ABN), a past President of the British Peripheral Nerve Society (BPNS), and a past President of the international Peripheral Nerve Society (PNS). She was elected a Fellow of the Academy of Medical Sciences in 2020.
David is Professor of neurology and neurobiology at the University of Oxford and honorary consultant neurologist. He is head of the Division of Clinical Neurology at Oxford. His sub-specialty interest is peripheral neuropathy and neuropathic pain; he administers the neuropathy and pain channelopathy clinic at Oxford University Hospitals. He completed neurology training in London and moved to the Nuffield Department of Clinical Neuroscience, Oxford in 2012. He is currently a senior Wellcome clinical scientist. He was bestowed with the Patrick D Wall medal in pain research by the Royal College of Anaesthetists in 2016, was appointed Honorary Skou professor, Aarhus University 2019 and is a Fellow of the Academy of Medical Sciences. His research interest is to understand the process of nerve injury and repair and prevent unwanted outcomes such as neuropathic pain. He takes a broad experimental approach to this problem ranging from understanding ion channel biology to clinical trials.
Luis Querol (Valencia, 1980) graduated in Medicine at the University of Oviedo. He completed his residency in Neurology at the Santa Creu i Sant Pau Hospital in Barcelona. In 2009 started his Neuroimmunology fellowship in the group of Prof. Isabel Illa and in 2012, joined the group of Dr. Kevin O’Connor, Department of Neurology, Yale University (USA), where he developed projects related to autoantibodies in multiple sclerosis and myasthenia gravis.
Supervised by Prof Illa, he completed his PhD in Medicine at the Universidad Autónoma de Barcelona in 2013 thanks to studies that identified clinically useful antibodies in autoimmune neuropathies. In particular, these studies describe anti-contactin antibodies in a specific subgroup of patients with CIDP. He is currently appointed principal investigator for the Autoimmune Neurology Program of the ERN-NMD Neuromuscular Sant Pau. Luis Querol received the Best Young Clinical Researcher 2013 Award from CIBERNED, the PK Thomas Award for best presentation in the field of neuropathies of the European Federation of Neurological Societies in 2014, the Grifols Institute’s SPIN Award (2016), the Oscar award of the AQuAS agency of Catalonia (2017) and the Scientific Award for Neuromuscular Diseases of the Spanish Society of Neurology (2019), all of them for his work with autoantibodies in CIDP.
Peter Goadsby is the Director of the National Institute for Health Research – Wellcome Trust King’s Clinical Research Facility (CRF). He leads the Biomedical Research Council Themes; Clinical Research Facility, and Pain and Headache. He is also the National Lead for Neurological Disorders for the Clinical Research Network, NIHR UK, a Trustee of the Organisation for the Understanding of Cluster Headache (OUCH UK) and Chair of the Scientific Programme Committee, Migraine Trust International Symposium. His major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into their better management.
Dr Holland is a Senior Lecturer at King’s College London. He originally trained in Neuroscience at the University of Glasgow, before undertaking his PhD in migraine at the Institute of Neurology, UCL. After a postdoctoral fellowships at UCSF and the University of Edinburgh, he established his independent laboratory at King’s in 2014. His research focuses on the underlying biological mechanisms for migraine and other headache disorders and he was recently recognized as one of the future leaders in pain research by the medical research foundation.
Neuropsychiatry of Pain Session
Dr. Atlas received her B.A. in psychology from The University of Chicago in 2003, and her Ph.D. in psychology in 2011 from Columbia University, where she studied under the mentorship of Dr. Tor D. Wager. Her doctoral work combined functional magnetic resonance imaging, experimental psychology, and psychopharmacology to examine the mechanisms by which beliefs and expectations influence pain and its modulation. Dr. Atlas’s postdoctoral research was conducted in Dr. Elizabeth A. Phelps’s laboratory at New York University, where she extended computational models of decision-making to isolate components of expectancy, and to understand how these components influence physiological and neural markers of aversive learning. In July 2014, Dr. Atlas joined NIH as an NCCIH investigator and chief of the Section on Affective Neuroscience and Pain. She also holds joint appointments with the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA). Dr. Atlas’s lab, the Section on Affective Neuroscience and Pain, focuses on characterizing the psychological and neural mechanisms by which expectations and other cognitive and affective factors influence pain, emotional experience, and clinical outcomes. The lab’s approach is multi–modal, integrating experimental psychology, neuroimaging, psychophysiology, computational approaches, and other interventions to understand how psychological and contextual factors influence subjective experience. Current projects focus on dissociating components of expectancy (e.g., instructions vs. conditioning; stimulus vs. treatment expectancies), relating pain with other types of hedonic affective responses, and understanding social influences on pain (e.g. patient-provider interactions; health disparities).
Flavia Mancini is a neuroscientist leading the NoxLab at the Department of Engineering, University of Cambridge. She combines behavioural, computational, and neuroimaging tools to understand pain perception and behaviour in humans.Flavia trained at the University of Milan and University College London. Currently, she is a Career Development Award fellow at the University of Cambridge, funded by the Medical Research Council.
Apkar Vania Apkarian is a professor of physiology, anesthesiology, and physical medicine and rehabilitation at Northwestern University in the Feinberg School of Medicine. He has been a pioneer in the use of Magnetic resonance spectroscopy to study the neurochemistry of the brain and the development of novel analytical approaches to studying consciousness, including the first demonstration of the brain’s small-world network properties using fMRI. In 2008, Dr. Apkarian proposed the theory that chronic pain is a form of emotional learning, which popularized the study of reward learning within the pain research field. Dr. Apkarian earned a master’s degree in electrical engineering from the University of Southern California and earned a Ph.D. in neuroscience from the State University of New York Upstate Medical University in Syracuse, New York.
Movement Disorders Session
Anette Schrag is a Professor of Clinical Neurosciences at the UCL Queen Square Institute of Neurology, London. She trained in neurology in Berlin and London and obtained a PhD at University College London. Her research interests include clinical, epidemiological and translational aspects of movement disorders, in particular Parkinson’s disease. She runs several clinical trials in Parkinson’s disease and has a particular interest in the prodromal phase of Parkinson’s disease. She is Vice-chair of the International Parkinson’s Disease and Movement Disorders Society (MDS) Non-motor Symptoms Group and chairs the MDS Ratings Scales Review Committee.
Anthony E. Lang MD, with FRCPC was trained in Medicine and Neurology at the University of Toronto. He subsequently completed a clinical research fellowship with Professor C.D. Marsden at King’s College Hospital and the Institute of Psychiatry in London England. Following this, in 1982 he returned to Toronto where he subsequently developed the Movement Disorders Clinic at the Toronto Western Hospital (TWH). He is currently professor in the Department of Medicine (Neurology) at the University of Toronto, director of the Morton and Gloria Shulman Movement Disorders Clinic at TWH, the Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, the Lily Safra Chair in Movement Disorders at the University Health Network in Toronto, Ontario, Canada, director of the University Health Network and the University of Toronto Edmond J. Safra Program in Parkinson’s Disease and is the director of the Division of Neurology at the University of Toronto. His research has involved all aspects of Parkinson’s disease and other movement disorders with over 550 peer-reviewed publications in leading medical journals. He was one of the founding members of the Parkinson Study Group as well as the international Movement Disorder Society and has served on the executives of both groups. Dr. Lang is currently the co-Editor-in-Chief of the journal Movement Disorders.
Anthony Schapira is head of the Department of Clinical Neurosciences at UCL Institute of Neurology (ION), Professor of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (NHNN) and the Royal Free Hospital. He undertook his undergraduate training as a Scholar at Westminster Medical School. He completed post-graduate training in London and was appointed to the University Chair of Clinical Neurosciences in 1990. He is currently Vice Dean of the University College London Medical School, and Director of the Royal Free Campus and was a visiting Professor at Harvard in 2009 and at Yale in 2010. He is co-Editor in Chief of the European Journal of Neurology, and is on several Editorial Boards of neurology and neuroscience journals. He was elected a Fellow of the Academy of Medical Sciences in 1999.
Malú Tansey obtained her BS/MS in biological sciences from Stanford University and her PhD in physiology from The University of Texas Southwestern Medical Center in Dallas. Dr. Tansey spent two years in the biotech sector in Los Angeles after post-doctoral training at Washington University in St. Louis before returning to academia as an assistant professor of physiology at UT Southwestern. She became a tenured associate professor of physiology in 2008 at UTSW and moved to Emory University in Atlanta in 2009, where she became professor of physiology and director of the Center for Neurodysfunction and Inflammation.
She is now a professor of neuroscience and director of the Center for Translational Research in Neurodegenerative Disease and the first endowed chair of the Fixel Institute for Neurological Diseases at the University of Florida in Gainesville. The general research interests of Dr. Tansey’s laboratory include investigating mechanisms underlying the role of immune and inflammatory responses in health and disease, in particular the role and regulation of central and peripheral inflammatory and immune system responses in modulating the gene-environment and gut-brain axis interactions that determine risk for development and progression of neurodegenerative diseases like Parkinson’s disease, Alzheimer’s and related dementias, and neuropsychiatric diseases like depression.
Hugh Markus is Professor of Stroke Medicine and Honorary Consultant Neurologist in the Department of Clinical Neurosciences at the University of Cambridge, UK. His undergraduate training was at the Cambridge and clinical medical training at the University of Oxford. He trained in Medicine at Oxford and Nottingham and in Neurology in London before being appointed as Senior Lecturer and then Reader in Neurology at King’s College London. He then moved to Professor of Neurology at St George’s, University of London, before moving to his current post in 2013.
He spends approximately half of his time in clinical care of stroke patients, including hyperacute stroke care as well as specialist stroke interests including running a National CADASIL Clinic. His research applies genetic and imaging techniques to investigate the pathogenesis of stroke and develop new treatments. He was disease lead for the Wellcome Trust Case Control Consortium 2 (WTCCC2) ischaemic stroke study and established the METASTROKE Genetics consortium. He has a particular interest in small vessel disease and vascular cognitive impairment, using MRI to investigate disease mechanisms and explore why the disease causes cognitive impairment, and developing new treatment approaches. He is Editor-in-Chief of the International Journal of stroke.
Prof. Steven M. Greenberg is Professor of Neurology at Harvard Medical School, Vice Chair of Neurology for Faculty Development and Promotions, and John J Conway Endowed Chair in Neurology at Massachusetts General Hospital. Under Prof. Greenberg’s leadership, the MGH Hemorrhagic Stroke Research Program has become internationally recognized for ground-breaking studies on the causes, diagnosis, and treatment of the major small vessel disease cerebral amyloid angiopathy (CAA). Among Prof. Greenberg’s milestones in the CAA field have been developing and validating the widely adopted Boston Criteria, applying amyloid imaging to CAA detection, characterizing the syndrome of CAA-related inflammation, and designing the foundation for the first CAA immunotherapy treatment trial. Prof. Greenberg is also a leader in the broader stroke and vascular cognitive impairment fields, receiving the 2017 AHA Feinberg Award and serving as PI of the NIH-funded MarkVCID consortium for biomarkers of vascular cognitive impairment, co-PI of the NIH-funded DISCOVERY network for post-stroke cognitive impairment and dementia, 2014-2016 chair of the NIH Acute Neural Injury and Epilepsy study section, chair of the 2013 and 2014 AHA International Stroke Conferences, and session co-chair of the 2013 NINDS Alzheimer’s Disease-Related Dementias Workshop. Among Prof. Greenberg’s >300 original reports and >90 review articles/chapters are authoritative review publications in Lancet Neurology on microbleeds (2009), microinfarcts (2012), and outcome markers for CAA trials (2014) and in Nature Review Neurology on the relationship between CAA and Alzheimer disease (2020).
Keith Muir – Speaker
Stroke neurologist and SINAPSE Chair of Clinical Imaging at University of Glasgow, Queen Elizabeth University Hospital, and Clinical Director for Stroke, Greater Glasgow & Clyde South Sector. Main scientific interests include the application of advanced brain imaging to clinical trials as a tool for translational research. Has been Chief Investigator for trials of thrombolysis (ATTEST, ATTEST-2), thrombectomy (PISTE), advanced imaging selection in thrombolysis (PRACTISE), MRI-selection in stroke of unknown onset time (WAKE-UP), and minor stroke or TIA (TEMPO-2). Has also led trials of physiological management (SELESTIAL), stem cell therapy (PISCES 1 and 2) and combined novel imaging and therapeutic methods (POST-IT).
Infectious Diseases Session
Tom Solomon is the Director of the National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections; Head of the Brain Infections Group; Professor of Neurological Science; Honorary Consultant Neurologist, Walton Centre NHS Foundation Trust and Royal Liverpool University Hospital.
He studied medicine at Wadham College, Oxford, before undertaking a PhD on central nervous system infections in Vietnam, with a Wellcome Trust Advanced Training Fellowship. He then became a Clinical Lecturer in Neurology, Medical Microbiology and Tropical Medicine at the University of Liverpool, and was awarded a Wellcome Trust Career Development Fellowship. This included two years as a visiting scientist at the University of Texas Medical Branch, Galveston, Texas. He was made a Senior Lecturer in Neurology in Liverpool in 2005, and awarded a Medical Research Council Senior Clinical Fellowship the same year. He became Chair of Neurological Science in 2007, and was Director of the newly formed Institute of Infection and Global Health in 2010-2017.
His research interests include emerging Infections, particularly those that affect the brain. He heads the Liverpool Brain Infections Group, which works to reduce the burden of neurological disease in the UK and globally, through research, training and capacity building, and public engagement.
Traumatic Brain Injury Session
Professor David Sharp is a neurologist and Centre Director of UK DRI Care Research & Technology, focusing on using technology to enhance the lives of people living with dementia. He is also Scientific Director of the Imperial College Clinical Imaging Facility and Associate Director of the Imperial Centre for Injury Studies. His research programme aims to improve clinical outcomes after dementia and traumatic brain injury (TBI), focusing on common cognitive impairments in domains such as memory and attention. He uses cognitive neuroscience and advanced neuroimaging to investigate the effect of brain injury on brain network function and the effects of inflammation and neurodegeneration. His word has explored how new treatments of cognitive impairment can be personalised and his current work focuses on harnessing neurotechnology development to improve the lives of those living with dementia and the effects of brain injury.
Prof Anderson is Head, Psychology, The Royal Children’s Hospital, Professorial Fellow, Paediatrics & Psychology, University of Melbourne, and Director, Clinical Sciences Research, Murdoch Children’s Research Institute. Her research and clinical interests are in disorders of childhood that impact on the brain, including both developmental and acquired disorders. Her recent work has focussed on translating her early career findings into clinical practice to optimise child outcomes from brain injury. Major translational achievements include: i) publication of the Test of Everyday Attention for Children, used by psychologists across the world; ii) development of easily accessed, low burden, e-health approaches to parent-focused psychosocial treatments as a means of maximising child outcomes; iii) development of a novel iPad delivered tool for assessing social cognition (PEERS).
Prof Anderson has authored over 500 peer reviewed publications and 6 books, and her research has attracted $45M in competitive grant funding. She is an Associate Editor for Neuropsychology (APA) and the J Neuropsychology (BPS, UK). She is a Fellow of the Academy of Social Sciences of Australia, the Aust Psychological Society and the Aust Academy of Health and Medical Sciences, and past president of the International Neuropsychological Society.
Nicholas Wood is Research Director of the UCL Institute of Genetics and is Galton Professor of Genetics. He qualified in medicine from Birmingham University in 1986 and undertook doctoral research at the University of Cambridge and was awarded a PhD in 1994. He has been a Senior Lecturer, Reader and Professor at the Institute of Neurology, University of London since 1995. He is currently a Consultant Neurologist, Head of the Department of Molecular Neuroscience and runs the Neurogenetic Laboratory at the UCL National Hospital for Neurology and Neurosurgery and the Institute of Neurology. In 2004 he was made a Fellow of the Academy of Medical Sciences. His primary research interest is the genetics of neurological disease with an emphasis on the genetics of Parkinson’s disease and the ataxias. He has published over 270 peer reviewed articles and is on the board of several international neuroscience journals
Professor Michael G Hanna is a Consultant Neurologist with a longstanding clinical and research interest in muscle diseases and is head of the Queen Square muscle disease clinical service. Professor Hanna is also Director of the UCL Institute of Neurology-Newcastle University MRC Centre for translational research in neuromuscular diseases.
Michael is a senior member of the North American Muscle Study Group – a consortium of scientific investigators who are committed to running controlled clinical trials for neuromuscular diseases. He is also corresponding member of the American Neurological association, member of the World Muscle Society and is a Guarantor of Brain.Michael qualified inMedical Biochemistry and then in Medicine at the University of Manchester andundertook postgraduate medical and neurological training posts in Newcastle, Oxford and London. He was an MRC training fellow to Professor Anita Harding undertaking his medical doctorate research in the genetics of mitochondrial diseases. He became a consultant at the National Hospital and Senior Lecturer in the Institute of Neurology in 1997 and Professor in Clinical Neurology in 2006.
He has a long-standing research interest in elucidating molecular genetic mechanisms in mitochondrial diseases and muscle/neurological channelopathies and also in the development of improved genetic diagnostics. He leads the UK national diagnostic reference laboratory and advisory service for channelopathies and co-leads a similar service for mitochondrial diseases. He has published over 170 peer reviewed original research papers including New England Journal of Medicine, American Journal of Human Genetics, Lancet Neurology and Lancet, and has held the position of deputy Editor of the Journal of Neurology, Neurosurgery and Psychiatry since 2003.
Francesco Muntoni is a Professor of Paediatric Neurologist, trained in Italy but working in UK since 1993. He is the Director of the Dubowitz Neuromuscular Centre, at the UCL Institute of Child Health and Great Ormond Street Hospital for Children, London, UK. In the Institute he has led the Developmental Neuroscience Programme (between 2008 and 2017) and he currently is Theme Lead in the Novel Therapies of the Biomedical Research Centre in the Great Ormond Street Hospital. Since 2008 he has worked very closely with the team at the UCL Institute of Neurology, lead by Prof Mike Hanna, and he has been a co-director of the MRC Centre for Neuromuscular Diseases at UCL.
Francesco Muntoni has an interest in pathogenesis, deep phenotyping, novel gene identification and translational research aspects especially in Duchenne muscular dystrophy and spinal muscular atrophy. He is involved in several natural history studies and clinical trials. His research funded by the Department of Health, MRC and the European commission lead to the development and early clinical trials of 2 morpholino antisense oligonucleotides (eteplirsen and goldodirsen), now approved by FDA, that induce partial correction of the processing defect of the DMD gene in boys with Duchenne muscular dystrophy and eligible mutations. He is the UK chief investigator for clinical trials on Duchenne muscular dystrophy, myotubular myopathy and spinal muscular atrophy, including adeno associated virus trials.
Michael Zandi trained in medicine in Cambridge and in neurology in Cambridge, Norwich and London with his PhD in Cambridge on neuropsychiatric lupus and NMDAR encephalitis. He is consultant neurologist at the National Hospital, Queen Square, and honorary associate professor at the UCL Queen Square Institute of Neurology. He has worked on autoimmune encephalitis and it’s presentations in psychiatric disease. He co-chairs the encephalitis meeting at the UCL Queen Square and UCLH National Hospital for Neurology and Neurosurgery since 2017, and weekly Covid-19 neurology meeting there since April 2020. He and his colleagues are working on the neurological and psychiatric complications of Covid-19, T cell biology of autoimmune encephalitis with MRC support, neuroimmunology of catatonia with Wellcome Trust support, and biomarkers of neuroimmunological disorders.
Markus is Professor of neuropathology at the University Medical Center Hamburg-Eppendorf. He is Director of the Institute of Neuropathology where he also serves as the Chairman of the Diagnostic Center. His scientific interest lies in translational neuropathology focusing on transmissible spongiform encephalopathy and in other pathogen-caused neurological diseases. He is the recipient of numerous scientific awards and since 2019 serves as editor in chief of “Brain Pathology”.
Dr. Nordvig is a U.S. board-certified neurologist at NY Presbyterian/Columbia University Irving Medical Center, and a postdoctoral fellow in Behavioral Neurology and Neuropsychiatry in the Division of Aging and Dementia at the Neurological Institute. She has applied her behavioral neurology and neuropsychiatry training to building an outpatient clinical and translational research program in post-COVID encephalopathy. Some of her findings are published in Neurology: Clinical Practice, Nature Medicine, npj Nature Parkinson’s Disease, and Acta Neuropathologica. She has also presented on this topic at the Cold Spring Harbor Laboratory Conference on Neurodegeneration, and is teaching a Continuing Medical Education course. Dr. Nordvig is funded through a T32 NIH grant as well as a National Institute on Aging Alzheimer’s Disease Research Center Career Development Award (through which she is studying plasma biomarkers of neurodegeneration in COVID-19). She also participates in the NIH C4R Cohort of Cohorts for COVID-19 Research, on the Neurocognition and Questionnaire subcommittees.
After serving as neurological consultant for myriad neurological inpatient complications of COVID-19, Dr. Nordvig returned to her outpatient cognitive practice to a new group of adult patients of all ages with persistent encephalopathy or “brain fog,” despite symptoms during acute COVID-19. Dr. Nordvig is working to characterize post-COVID-19 encephalopathy through neuropsychological phenotyping, biofluidics and imaging techniques, in search of symptomatic and mechanistic treatments. Her goal is to understand the implications of post-COVID-19 encephalopathy (as a model of acute systemic inflammation) for neurodegeneration – it a risk factor, an early biomarker, or a trigger?
David Isenberg is the Versus Arthritis Professor and Academic Director of the UCL Centre for Rheumatology and co -director of the Versus Arthritis Adolescent Centre of Excelence. His major research interests include the structure, function, origin and pathogenecity of anti-DNA antibodies and antiphospholipid antibodies. he has a long standing interest in the development and evaluation of “tools” used to assess patients with Systemic Lupus Erythematosus, Myositis, Anti-Phospholipid Antibody Syndrome and Sjogren’s Syndrome.
After gaining his MD in 1984, he held a research fellowship at the New England Medical Centre in Boston where his interest in autoantibody structure/function originated, developing into a specialist involvement in autoimmune rheumatic diseases, notably systemic lupus erythematosus, Sjögren’s syndrome, myositis and the anti-phospholipid antibody syndrome. He was appointed Professor in 1991and has been the academic director of Rheumatology UCL London since 1996 he has been past President of the British Society for Rheumatology, past chair of the British Isles Lupus Assessment Group (BILAG); the Systemic Lupus International Collaborating Clinics (SLICC) group and co chair of the International Myositis Assessment (IMACS) group. He has been elected to Fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.